当前位置：
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-10-21 , DOI: 10.1038/s41408-024-01155-y Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
中文翻译：
1/2 期 DREAMM-6 试验 A 组的结果：belantamab mafodotin 联合来那度胺加地塞米松治疗复发/难治性多发性骨髓瘤患者
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-10-21 , DOI: 10.1038/s41408-024-01155-y Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
|
中文翻译：
1/2 期 DREAMM-6 试验 A 组的结果：belantamab mafodotin 联合来那度胺加地塞米松治疗复发/难治性多发性骨髓瘤患者
京公网安备 11010802027423号